Search

Search Constraints

You searched for: Author/Creator Quirk, Daniel

Search Results

1. An economic evaluation of tofacitinib for the treatment of moderately-to-severely active ulcerative colitis: modeling the cost of treatment strategies in the United States. (2nd September 2019)

2. Efficacy of Tofacitinib in Patients With Ulcerative Colitis by Prior Tumor Necrosis Factor Inhibitor Treatment Status: Results From OCTAVE Induction and Maintenance Studies: 640. (October 2017)

3. Impact of Baseline Corticosteroid Therapy on Tofacitinib Induction Efficacy and Infection Risk in Patients With Ulcerative Colitis: Data From Global Clinical Trials: 706. (October 2019)

4. Incidence of Venous Thromboembolic Events in Patients With Ulcerative Colitis Treated With Tofacitinib in the Ulcerative Colitis Clinical Development Program: 644. (October 2019)

6. Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis—two cases in real world clinical practice. Authors' reply. Issue 11 (19th May 2020)

7. Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib—Implications for Cardiovascular Risk and Patient Management. Issue 6 (17th May 2021)

8. Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib—Implications for Cardiovascular Risk and Patient Management. Issue 6 (1st September 2020)

9. Predictors of Delayed Response to Tofacitinib: Results of the OCTAVE Open Study for Delayed Responders: 798. (October 2019)